ARYA Sciences Acquisition Corp IV Announces Pricing of $130 Million Initial Public Offering
26 Février 2021 - 2:04AM
ARYA Sciences Acquisition Corp IV (the “Company”), a special
purpose acquisition company formed for the purpose of entering into
a combination with one or more businesses or entities, today
announced the pricing of its initial public offering of 13,000,000
Class A ordinary shares at a price of $10.00 per share. The Class A
ordinary shares will be listed on The Nasdaq Capital Market and
trade under the ticker symbol “ARYD” beginning on February 26,
2021.
While the Company may pursue an initial business combination
target in any business or industry, it intends to focus on the
healthcare industry in the United States and other developed
countries. The Company intends to focus on target businesses with
valuations of $300 to $500 million or more and that have the
potential to be $1 billion or more market capitalization companies.
The Company is led by Chairman Joseph Edelman, Chief Executive
Officer Adam Stone, Chief Financial Officer Michael Altman and
Chief Business Officer Konstantin Poukalov.
Goldman Sachs & Co. LLC and Jefferies LLC are serving as
joint book-running managers for the offering. The Company has
granted the underwriters a 45-day option to purchase up to an
additional 1,950,000 Class A ordinary shares to cover
over-allotments, if any, at the initial public offering price.
The offering is being made only by means of a prospectus. When
available, copies of the prospectus may be obtained from: Goldman
Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street,
New York, New York 10282, telephone: (212) 902-1171 or email:
Prospectus-ny@ny.email.gs.com; or Jefferies LLC, Attn: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10002, by telephone: 877-821-7388 or by email:
Prospectus_Department@Jefferies.com.
The registration statement relating to the securities was
declared effective on February 25, 2021 by the U.S. Securities and
Exchange Commission (the “SEC”). This press release shall not
constitute an offer to sell or the solicitation of an offer to buy,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
The offering is expected to close on March 2, 2021, subject to
customary closing conditions.
Cautionary Note Concerning Forward-Looking
Statements
This press release contains statements that constitute
“forward-looking statements,” including with respect to the
proposed initial public offering and the anticipated use of the net
proceeds. No assurance can be given that the offering discussed
above will be completed on the terms described, or at all, or that
the net proceeds of the offering will be used as indicated.
Forward-looking statements are subject to numerous conditions, many
of which are beyond the control of the Company, including those set
forth in the “Risk Factors” section of the Company’s registration
statement and preliminary prospectus for the Company’s offering
filed with the SEC. Copies are available on the SEC’s website,
www.sec.gov. The Company undertakes no obligation to update these
statements for revisions or changes after the date of this release,
except as required by law.
Contact
Michael AltmanChief Financial Officer of ARYA Sciences Holdings
Corp IV(646) 205-5300arya4@perceptivelife.com
ARYA Sciences Acquisitio... (NASDAQ:ARYD)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
ARYA Sciences Acquisitio... (NASDAQ:ARYD)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024